FDA Grants Accelerated Approval to AstraZeneca's Ultomiris for IgA Nephropathy

The U.S. Food and Drug Administration has granted accelerated approval to Ultomiris (ravulizumab-cwvz) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression, AstraZeneca said on Oct. 21, 2026. The decision makes the long-acting infusion from Alexion, AstraZeneca Rare Disease, the first C5 complement inhibitor cleared in the U.S. for the chronic kidney disease, and gives the Boston-based unit a fifth approved indication for the drug.

Disease background

IgAN is a rare, inflammatory kidney disease in which abnormal IgA antibodies form immune complexes that lodge in the kidneys. Those deposits activate the complement system, part of the innate immune response, and the resulting inflammation damages the glomeruli that filter blood. AstraZeneca says the disease affects more than 200,000 people in the U.S. Many patients have no symptoms early on, so the condition is often found only after irreversible damage has occurred.

Protein in the urine is the main marker clinicians track. According to the company, about half of people with IgAN who have elevated urine protein or reduced kidney function are at high risk of progressing to kidney failure within 10 years of diagnosis, which can mean dialysis or a transplant. That link is why the FDA allows proteinuria reduction to support accelerated approval, while asking sponsors to prove later that their drugs slow the decline in estimated glomerular filtration rate (eGFR).

Ultomiris blocks C5, a protein near the end of the complement cascade. It was first approved in the U.S. in 2018 and is already used for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis and neuromyelitis optica spectrum disorder. Like Soliris, it carries a boxed warning for serious meningococcal infections and is available only through a restricted Risk Evaluation and Mitigation Strategy program that requires vaccination.

Industry implications

The approval extends a complement inhibitor built for ultra-rare blood and neurological disorders into a much larger kidney population. For Alexion, IgAN is a lifecycle opportunity: it adds a fifth label to its main franchise at a time when lower-cost biosimilar versions of its older C5 drug, Soliris, have been approved in the U.S. Every-eight-week dosing is also a practical selling point for nephrologists and infusion centers managing patients on long-term therapy.

The decision also confirms the regulatory path that has reshaped IgAN drug development. Surrogate endpoints based on proteinuria have allowed several sponsors to reach the market years before final kidney function data are available. The trade-off is uncertainty. The label states that it has not been established whether Ultomiris slows kidney function decline, and that question will be settled only by the full I CAN results.

Competitive and supply chain implications

Ultomiris enters a crowded and fast-moving field. Physicians already combine blood pressure medicines and SGLT2 inhibitors with targeted therapies such as Novartis' oral factor B inhibitor Fabhalta, which works earlier in the complement pathway. B-cell approaches have also gained ground: Otsuka's Voyxact (sibeprenlimab) received accelerated approval in November 2025 and Vera Therapeutics' Trutakna (atacicept) in July 2026, and Vertex's povetacicept has an FDA target date of Nov. 30, 2026, as reported by Medical Daily.

Against that backdrop, Alexion's argument rests on mechanism and convenience: a terminal complement blocker with sustained inhibition and infrequent dosing. Oral drugs and self-injected B-cell therapies may appeal more to patients who want to avoid infusions, so prescribing patterns will likely depend on disease severity, payer coverage and how physicians sequence or combine therapies. On the supply side, Ultomiris is an established commercial biologic, so the IgAN launch draws on existing production and distribution networks, though growth in a broader kidney population will add demand for infusion capacity and the vaccination steps tied to the REMS.

Regional implications

The U.S. approval is the first major regulatory win for Ultomiris in IgAN and sets the template for other markets. AstraZeneca said submissions based on the interim I CAN analysis are under review in Japan and additional countries; the release did not detail European or Chinese filings for this indication. I CAN itself is a global study, with planned enrollment of about 510 participants in 28 countries across North America, South America, Europe, Asia and Australia, which should support filings in several regions.

IgAN is more common in East Asia than in Western populations, which makes Japan and other Asian markets important for any IgAN therapy. Reimbursement bodies in Europe and Asia often weigh hard outcomes such as kidney failure more heavily than surrogate markers, so the week-106 eGFR data may matter more for pricing and access outside the U.S.

What comes next

• Late-breaking I CAN results on proteinuria and hematuria are scheduled for presentation at ASN Kidney Week 2026 in Denver on Oct. 23.
• The trial continues through 106 weeks of blinded treatment, with eGFR change as the primary endpoint intended to support traditional approval.
• Regulatory reviews based on interim data are pending in Japan and other countries.
• The FDA decision on Vertex's povetacicept, reported for Nov. 30, 2026, will add another competitor to the IgAN field.
• Commercial uptake will depend on payer coverage decisions and how nephrologists position C5 inhibition alongside existing therapies.

Sources

• AstraZeneca: Ultomiris received accelerated approval in the US for adults with primary IgA nephropathy (Oct. 21, 2026)
• U.S. FDA: Ultomiris prescribing information
• Medical Daily: IgA nephropathy approvals and pending FDA decisions

Image: Alexion, AstraZeneca Rare Disease building, by ajay_suresh via Wikimedia Commons, CC BY 2.0. Cropped and edited by Credence Research.